Cited by Prurigo nodularis

Des lésions bulleuses cutanées prurigineuses DOI

Françoise Dolbeault,

Floriane Lebas,

A. Benyamine

et al.

La Revue de Médecine Interne, Journal Year: 2025, Volume and Issue: 46(3), P. 181 - 182

Published: Feb. 24, 2025

Citations

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report DOI

Nikoo Mozafari

Clinical Case Reports, Journal Year: 2025, Volume and Issue: 13(3)

Published: March 1, 2025

Recent advancements in understanding the potential pathogenesis of prurigo nodularis (PN) have paved way for development new, targeted therapies. Emerging evidence suggests that JAK inhibitors may provide a safe and effective treatment option both atopic non-atopic PN. Here, we present case refractory PN successfully treated with tofacitinib.

Language: Английский

Citations

Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence DOI

Abullah Demirbas,

Esin Diremsizoğlu,

Gizem Cınar

et al.

Archives of Dermatological Research, Journal Year: 2025, Volume and Issue: 317(1)

Published: March 11, 2025

Language: Английский

Citations

Taiwanese Dermatological Association consensus for the diagnosis and management of prurigo nodularis DOI

Cheng‐Che E. Lan, Wen‐Hung Chung, Yang‐Yi Chen

et al.

Dermatologica Sinica, Journal Year: 2025, Volume and Issue: 43(1), P. 2 - 13

Published: Jan. 1, 2025

Language: Английский

Citations

Endothelin‐1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells DOI

Lai‐San Wong, Jenq‐Lin Yang,

Y. Yen

et al.

Allergy, Journal Year: 2025, Volume and Issue: unknown

Published: April 18, 2025

Language: Английский

Citations

Diseases from the Spectrum of Dermatitis and Eczema: Can “Omics” Sciences Help with Better Systematics and More Accurate Differential Diagnosis? DOI

Radosław Śpiewak

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10468 - 10468

Published: June 21, 2023

Researchers active in the field of inflammatory skin diseases from spectrum dermatitis and eczema are well aware a considerable overlap clinical pictures proposed sets diagnostic criteria for these diseases, which can hardly be overcome through or epidemiological research. In effect, patients included studies based on vague overlapping criteria, while heterogeneous study populations may, turn, lead to non-representative outcomes continued confusion. this narrative review, systematics is origins causative factors pathomechanisms involved. Difficulties differentiating between discussed, extent advances “omics” sciences might help them considered. Of all research field, more than 90% published papers were devoted atopic dermatitis, with striking underrepresentation other eczema, conditions collectively exceed rates by far. A greater effort urgently needed tackle dermatitides, like allergic, irritant protein contact as radiation, seborrheic, stasis autoimmune dermatitis. Atopic findings should validated not only against healthy donors but also dermatitides. clinic-oriented approach future eczema.

Language: Английский

Citations

Circadian rhythm of cutaneous pruritus. DOI

Zichao Jiang,

Xiaoxue Sang,

Jianyun Lu

et al.

PubMed, Journal Year: 2024, Volume and Issue: 49(2), P. 190 - 196

Published: Feb. 28, 2024

One of the most common and significant symptoms for skin disorders is pruritus. Additionally, it serves as a catalyst exacerbation or reoccurrence diseases. Pruritus seriously affects patients' physical mental health, even quality life. It brings heavy burden to patients, families, whole society. The pathogenesis regulation mechanisms pruritus are complicated have not yet been elucidated. Previous clinical studies shown that itch worsens at night in scabies, chronic pruritus, atopic dermatitis, psoriasis, suggesting may change with circadian rhythm. Cortisol, melatonin, core temperature, cytokines, prostaglandins main regulatory factors rhythm Recent some CLOCK genes, such

Language: Английский

Citations

Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab DOI

Jennifer Astrup Sørensen,

Cæcilie Bachdal Johansen, Alexander Egeberg

et al.

JAAD Case Reports, Journal Year: 2024, Volume and Issue: 52, P. 146 - 149

Published: Aug. 23, 2024

Language: Английский

Citations

Dupilumab as a novel treatment option for prurigo nodularis DOI

Saeko Nakajima, Satoru Yonekura, Satoshi Nakamizo

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2023, Volume and Issue: 152(4), P. 870 - 872

Published: Aug. 23, 2023

Language: Английский

Citations

Current clinical practice of prurigo nodularis in Japan: A cross‐sectional web‐survey among dermatologists DOI

Hiroyuki Murota, Mai Matsumoto, Kazuhiko Arima

et al.

The Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Abstract Prurigo nodularis (PN) is a chronic inflammatory skin disease associated with intense pruritic nodules. The unclear patho‐etiological mechanisms of PN cause difficulty in management; and there paucity information on the current diagnosis treatment options for Japan. To describe management from dermatologists' perspective we conducted web‐based survey (UMIN Clinical Trial Registry UMIN000047643) 2022 among dermatologists Japanese commercially available physician panel, who had seen at least one patient within last 3 months. included 117 dermatologists. diagnosed mainly by confirming clinical signs interviews, while to assess severity PN, number nodules degree itching were primarily utilized. Topical corticosteroids antihistamines most used drugs, as recommended guidelines prurigo. Dermatologists' satisfaction decreased increasing assumed PN; almost 65% not satisfied severe PN. These results suggest need more effective medications diagnostic tools better

Language: Английский

Citations